Texas Equine Veterinary Association

Summer Symposium Edition The Remuda 2024

Texas Equine Veterinary Association Publications

Issue link: http://aspenedgemarketing.uberflip.com/i/1522623

Contents of this Issue

Navigation

Page 32 of 71

Break free Help your equine patients by controlling the clinical signs associated with osteoarthritis • 250 mg/ml in a 7.5 mL vial; more fl exibility in dosing a wide range of horses • With proper dosing at 3mg/kg, 4 injections needed to provide maximum therapeutic effect • FDA approved drugs ensure the manufacturing process is consistent to preserve the drug's quality • Proven effi cacy not limited to specifi c joints 1 As with all drugs, side effects may occur. For intramuscular use in horses only. Not for use in humans. Pentosan polysulfate sodium is a weak anticoagulant. Caution should be used when administering Zycosan if you are taking an anticoagulant. In case of accidental self-injection, seek immediate medical attention. If product comes into contact with skin, rinse skin thoroughly with water and seek medical attention if needed. Horses with hypersensitivity to pentosan polysulfate sodium should not receive Zycosan. Do not use Zycosan concurrently with other anticoagulant drugs. Do not use in horses with clotting disorders or within 24 hours of surgical procedures. Caution should be used when administering this drug before or after strenuous activities. Caution should be used when NSAIDS are administered concurrently due to the anticoagulant effects of Zycosan. If Zycosan and NSAIDS are used concurrently, horses should be monitored for hemorrhage or other clinical signs of abnormal bleeding. The safe use of Zycosan has not been evaluated in breeding, pregnant, or lactating horses. The safety of long-term repeat use of Zycosan has not been evaluated. The most frequently reported adverse reactions are injection site reactions, prolongation of coagulation parameters (activated partial thromboplastin time (aPTT) and prothrombin time (PT). Refer to the prescribing information for complete details or visit www.dechra-us.com. 1. Zycosan® Freedom of Information Summary NADA 141-559 © 2023 Dechra Veterinary Products. Dechra is a registered trademark of Dechra Pharmaceuticals PLC. Zycosan is a registered trademark of Dechra Limited; all rights reserved. E230089 To learn more about Zycosan ® , please scan the QR code or visit go.dechra-us.com/zycosan 24-hour Veterinary Technical Support available: (866) 933-2472 Nonurgent Technical Support available: support@dechra.com Important Satefy Information 250 mg/mL

Articles in this issue

Links on this page

view archives of Texas Equine Veterinary Association - Summer Symposium Edition The Remuda 2024